|
 Company: Roche Group, Basel, Switzerland
Company Description: Roche is the world’s largest biotech company, the world leader in in-vitro diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
Nomination Category: Management Awards Categories
Nomination Sub Category: Executive of the Year in Europe
Nomination Title: Dr. Severin Schwan, CEO, Roche Group
Tell the story about what this nominee achieved (up to 500 words). Focus on specific accomplishments, and relate these accomplishments to past performance or industry norms. Be sure to mention obstacles overcome, innovations or discoveries made, and outcomes:
On July 1, 2009 Dr. Severin Schwan lead the Roche Group in the development of a
program to ensure that poor countries would have access to Tamiflu incase of a
worldwide Influenza pandemic. The program is called the Tamiflu Reserves Program
(TRP), which will produce and store plenty of Tamiflu for countries in need at a
reduced price. Once a pandemic is announced by the World Health Organization the
Tamiflu reserves will be sent to governments in need. This program gives
governments the ability to access the vaccine in case of emergency without
spending more than they can afford. The Roche Group and Dr. Schwan are very
dedicated to helping others in need, which they clearly show with this generous
program.
Roche and Dr. Schwan received a tremendous honor in September when they were
rated by the Dow Jones Sustainability Index as the new Super Sector Leader in
the Healthcare division. They were also honored by the pan-European Dow Jones
STOXX Sustainability Index. This is the sixth consecutive year that Roche has
been included in these indexes, but for the first time they are now the leader
in healthcare sustainability worldwide. Dr. Schwan noted that commitment to
sustainability has made Roche so successful and that this honor drives them to
deliver more innovative medicines in the future.
In December, Dr. Severin Schwan announced Roche’s new Cobas 4800 System for lab
testing efficiency and molecular diagnostic needs. This new system works by
combining diagnostic HPV or gonorrhea tests with polymerase chain reaction (PCR)
technology to determine if there are risks for cancer. There are about 14
different genotypes in certain STDs, especially HPV, which put women at great
risk of developing cervical cancer. The Cobas 4800 System can detect all of
these dangerous genotypes. This new system is revolutionary and necessary for
doctors to make sure these genotypes are controlled. It is a simplified software
that tests samples, detects ricks and provides the results to prevent cancer
from developing. This new 4800 System shows the Roche Group’s dedication to
saving lives and helping develop new medical technology.
Dr. Severin Schwan continued to move Roche in the right direction financially in
2009. Total sales for the entire group reached 49.1 billion Swiss francs, which
is an increase of about 10% from 2008. Operating Profit before exceptional items
increased to over 15 billion Swiss francs (up 14%), which was brought on mostly
by the product improvements that were experienced in 2009.
List hyperlinks to any online news stories, press releases, or other documents that support the claims made in the section above. IMPORTANT: Begin each link with http://, and enclose each link in square brackets; for example, [http://www.youraddress.com]:
http://www.roche.com/med-cor-2009-07-01
http://www.roche.com/med-cor-2009-09-03b
http://www.roche.com/med-cor-2009-12-09b
http://www.roche.com/med-cor-2010-02-03
Provide a brief (up to 100 words) biography about this nominee:
Dr. Severin Schwan first joined the Roche Group in 1993 as a corporate finance
trainee, and in 2008 he was appointed CEO. During his career at Roche, Schwan
has held other positions such as Head of Finance & Administration in Brussels
(Belgium) and head of Global Finance & Services for Roche Diagnostics. He is
also currently on the Board of Directors for Chugai Pharmaceuticals in Japan,
and serves as a member of the IBLAC in Shanghai. He earned an economics and law
degree from the University of Innsbruck in 1991. Schwan also received a
doctorate in law in 1993 from the University of Innsbruck.
Copyright © 2010 Infogroup
|
